Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine Against Pulmonary Pneumococcal Infection

Vaccines - Switzerland
doi 10.3390/vaccines8020193
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

A Molecular Mucosal Adjuvant to Enhance Immunity Against Pneumococcal Infection in the Elderly

Immune Network
Infectious DiseasesImmunologyAllergy
2015English

Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100

PLoS ONE
Multidisciplinary
2012English

A Built-In Adjuvant-Engineered Mucosal Vaccine Against Dysbiotic Periodontal Diseases

Mucosal Immunology
AllergyImmunology
2018English

Efficacy of Pneumococcal Vaccine

Thorax
PulmonaryRespiratory Medicine
2003English

Comparative Preclinical Evaluation of AS01 Versus Other Adjuvant Systems in a Candidate Herpes Zoster Glycoprotein E Subunit Vaccine

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2016English

Clostridium Difficile Flagellin FliC: Evaluation as Adjuvant and Use in a Mucosal Vaccine Against Clostridium Difficile

PLoS ONE
Multidisciplinary
2017English

The TLR4 Agonist Adjuvant SLA-SE Promotes Functional Mucosal Antibodies Against a Parenterally Delivered ETEC Vaccine

npj Vaccines
Infectious DiseasesImmunologyPharmacology
2019English

Efficacy of Trivalent, Cold-Adapted, Influenza Virus Vaccine Against Influenza a (Fujian), a Drift Variant, During 2003–2004

Vaccine
Molecular MedicinePublic HealthVeterinaryMicrobiology EnvironmentalImmunologyInfectious DiseasesOccupational Health
2007English

Evaluation of Mucosal Vaccines Against Pneumococcal and Meningococcal Diseases

International Journal of Vaccines & Vaccination
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy